Could Valeant Pharmaceuticals Intl Inc Lose Strenght? The Stock Increases A Lot Today

 Could Valeant Pharmaceuticals Intl Inc Lose Strenght? The Stock Increases A Lot Today

The stock of Valeant Pharmaceuticals Intl Inc (TSE:VRX) is a huge mover today! About 707,378 shares traded hands. Valeant Pharmaceuticals Intl Inc (TSE:VRX) has declined 51.39% since April 7, 2016 and is downtrending. It has underperformed by 57.54% the S&P500.
The move comes after 6 months positive chart setup for the $8.59 billion company. It was reported on Nov, 11 by Barchart.com. We have $31.96 PT which if reached, will make TSE:VRX worth $2.92 billion more.

Valeant Pharmaceuticals Intl Inc (TSE:VRX) Ratings Coverage

Out of 3 analysts covering Valeant Pharmaceuticals International (TSE:VRX), 1 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 33% are positive. Valeant Pharmaceuticals International has been the topic of 16 analyst reports since October 20, 2015 according to StockzIntelligence Inc. The firm earned “Sector Perform” rating on Tuesday, September 20 by RBC Capital Markets. The company was maintained on Tuesday, January 26 by RBC Capital Markets. The stock of Valeant Pharmaceuticals Intl Inc (TSE:VRX) has “Outperform” rating given on Tuesday, October 20 by RBC Capital Markets. The firm has “Buy” rating by TD Securities given on Thursday, August 11. The firm has “Sector Perform” rating given on Wednesday, September 7 by RBC Capital Markets. RBC Capital Markets maintained the stock with “Sector Perform” rating in Tuesday, October 25 report. The stock of Valeant Pharmaceuticals Intl Inc (TSE:VRX) has “Sector Perform” rating given on Tuesday, October 11 by RBC Capital Markets. The firm has “Sector Perform” rating by RBC Capital Markets given on Friday, June 3. The stock of Valeant Pharmaceuticals Intl Inc (TSE:VRX) earned “Sector Perform” rating by RBC Capital Markets on Tuesday, May 24. RBC Capital Markets maintained the stock with “Sector Perform” rating in Monday, October 31 report.

More notable recent Valeant Pharmaceuticals Intl Inc (TSE:VRX) news were published by: Profitconfidential.com which released: “Valeant Pharmaceuticals Intl Inc: VRX Stock Rises Again” on November 10, 2016, also Bloomberg.com with their article: “Valeant Plunges Again, Warning ‘Could Still Be Surprises'” published on November 08, 2016, Fool.com published: “3 Figures in Focus When Valeant Pharmaceuticals Intl. Inc. Reports Its Q3 Results” on November 01, 2016. More interesting news about Valeant Pharmaceuticals Intl Inc (TSE:VRX) were released by: Investorplace.com and their article: “Why Valeant Pharmaceuticals Intl Inc (VRX), CVS Health Corp (CVS) and …” published on November 08, 2016 as well as Profitconfidential.com‘s news article titled: “Valeant Pharmaceuticals Intl Inc: Did VRX Stock Just Bottom?” with publication date: November 03, 2016.

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company has a market cap of $8.59 billion. The Firm is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It currently has negative earnings. It operates through two divisions: Developed markets and Emerging markets.

VRX.TO Company Profile

Valeant Pharmaceuticals International, Inc., incorporated on August 9, 2013, is a specialty pharmaceutical and medical device company. The Firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Firm operates through two divisions: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal (GI) disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses primarily on branded generics, OTC products and medical devices.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment